Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OR 462

Known as: OR-462, OR462 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
The efficacy of levo-DOPA in the treatment of Parkinson's disease is potentiated by blockade of its peripheral metabolism with… Expand
Is this relevant?
1992
1992
PET studies were performed to investigate the effects of a new cathechol-O-methyltransferase (COMT) inhibitor, nitecapone (OR-462… Expand
Is this relevant?
1992
1992
Nitecapone [3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione] [OR-462] is a catechol-O-methyltransferase inhibitor with… Expand
Is this relevant?
1991
1991
We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O… Expand
Is this relevant?
1991
1991
3-Nitropyrocatechols are very potent and selective inhibitors of catechol-O-methyltransferase (COMT). LD50 values of three of… Expand
Is this relevant?
1990
1990
3-O-Methyldopa (OMD) is the principal circulating metabolite formed from exogenously administered levodopa. We studied the effect… Expand
Is this relevant?
1990
1990
SummaryInteractions between a selective catechol-O-methyltransferase (COMT) inhibitor OR-462 and a monoamine oxidase (MAO)-A… Expand
Is this relevant?
1988
1988
A selective catechol-O-methyltransferase inhibitor, OR-462, was studied for its ability to affect pharmacokinetic properties of L… Expand
Is this relevant?
1988
1988
Catechol-O-methyltransferase (COMT) has an important role in the extraneuronal inactivation of catecholamine neurotransmitters… Expand
Is this relevant?
1988
1988
Novel bisubstituted catechols were found to be potent and highly selective COMT inhibitors in vitro. One of them, OR-462 (3-(3,4… Expand
Is this relevant?